Our life goal is to make yours better.

CVRx® is a privately held company founded in 2001 and headquartered in Minneapolis, U.S.A. Our vision is to advance health for people everywhere, giving each patient a fuller life. CVRx® pioneers unique therapies that harness and harmonize the body's natural systems, benefiting society and making CVRx® a universal role model in healthcare.


Pioneering a Unique Therapy

BAROSTIM NEO™ is the only device CE Marked for the separate indications of heart failure and resistant hypertension. Currently, BAROSTIM NEO™ is commercially available in over 20 countries and under clinical evaluation for the treatment of heart failure and hypertension in the United States.

Learn More About Barostim Neo™

Our Awards

CVRx® has received numerous awards throughout the years.
Click on a logo to learn more.
Awards Section

Our History

  • 2001

    CVRx® established in Minneapolis, Minnesota, USA

  • 2004

    First patient treated with the first-generation BAROSTIM THERAPY™ device in Bern University Hospital (Switzerland)

  • 2005

    First patient treated in the US

  • 2006

    Early findings from DEBuT-HT Hypertension trial, showing significant reductions in blood pressure, are presented at the American Heart Association congress

  • 2007

    First-generation BAROSTIM THERAPY™ device receives CE-mark approval for resistant hypertension

  • 2008

    Two-year results of DEBuT-HT Hypertension trial confirm first-generation BAROSTIM THERAPY™ device’s significant blood pressure reduction

  • 2011

    Introduction of the BAROSTIM NEO™ device, which receives CE-mark approval for resistant hypertension

  • Jun 2014

    Publication of a "Proof-of-concept" study in Heart Failure concluding that BAROSTIM NEO™ is safe and provides chronic improvement to patients

  • Sep 2014

    BAROSTIM NEO™ receives CE-mark approval for the treatment of heart failure

  • Dec 2014

    BAROSTIM NEO™ LEGACY granted Humanitarian Device Exemption by FDA for Hypertensive patients who were defined as responders to the Rheos Carotid Sinus Lead System

  • May 2015

    1000 patients treated with BAROSTIM THERAPY™

  • Jun 2015

    Results of BAROSTIM THERAPY™ for Heart Failure randomized study presented at several international congresses

  • Nov 2015

    Expedited Access Pathway designation granted by FDA for BAROSTIM THERAPY™ for the treatment of heart failure

  • Jun 2016

    First patients treated in pivotal trial evaluating BAROSTIM THERAPY™ in heart failure (BeAT-HF)

Expand History
Collapse History

Leadership Team

Board of Directors

Senior Management

EUROPE:  The BAROSTIM NEO™ System is CE Marked and approved for sale for hypertension patients in the European Union (EU). It is also CE Marked and approved for sale for heart failure patients in the EU.

CAUTION:  Investigational device. Limited by Federal (or United States) law to investigational use.
CAUTION:  Federal law restricts this device to sale by or on the order of a physician. Humanitarian Device. Authorized by Federal law for use in the treatment of resistant hypertensive patients implanted with the Rheos CSL leads.  The effectiveness of this device has not been demonstrated.

CANADA ONLY:  CAUTION: Exclusively for Clinical Investigations

For a list of all potential benefits and risks go to www.cvrx.com/benefit-risk-analysis/